Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

ooking statements, which express the current beliefs and expectations of the management of GPC Biotech AG and Pharmion Corporation, including statements relating to results of the SPARC trial and statements relating to the potential efficacy and safety profile of satraplatin. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2007, its Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either Pharmion or GPC Biotech. Forward-looking statements speak only as of the date on which they are made and neither Pharmion nor GPC Biotech undertakes any obligation to update these forward-looking statements, even if new information becomes availabl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... that a new market research report is available in ... http://www.reportlinker.com/p0369401/Dry-Powder-Inhalation.html ... the growing emphasis on drug self-administration for chronic conditions, ... availability of innovative inhaler device designs - is driving ...
... NEW YORK, Feb. 1, 2011 Reportlinker.com announces ... in its catalogue: Epoetin alfa ... http://www.reportlinker.com/p0366250/Epoetin-alfa---Comprehensive-patent-search.html Eliminate unnecessary risk with ... Pipeline Developer is a regularly updated, professional ...
Cached Medicine Technology:Reportlinker Adds Dry Powder Inhalation 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 2Reportlinker Adds Epoetin alfa - Comprehensive patent search 3Reportlinker Adds Epoetin alfa - Comprehensive patent search 4
(Date:4/23/2014)... April 23, 2014Men whose testosterone falls below normal levels ... be overweight and have heart disease and type 2 ... testosterone-deficient men for further testing and possible treatment is ... Health , a peer-reviewed publication from Mary Ann Liebert, ... Journal of Men,s Health website at ...
(Date:4/23/2014)... As evidence mounts showing the potential health benefits of ... people are taking supplements. And the chemical industry is ... supplements, health effects could deter growth, so the industry ... claims, according to the cover story in Chemical ... of the American Chemical Society. , Melody M. Bomgardner, ...
(Date:4/23/2014)... from the Cancer Science Institute of Singapore (CSI Singapore) ... cancer specific stem cell which causes gastric cancer. This ... for the treatment of this disease and other types ... Chan Shing Leng, Research Assistant Professor at CSI Singapore, ... of a cell surface protein, CD44v8-10, marks gastric cancer ...
(Date:4/23/2014)... Ritalin, may prevent the depletion of self-control, according to ... of the Association for Psychological Science. , Self-control can ... to focus attention on a boring textbook are hard ... for this difficulty: Exerting self-control for a long period ... on subsequent tasks. , "It is as if self-control ...
(Date:4/22/2014)... Government and industry leaders visited the New Jersey ... President Joel S. Bloom for the launch of ... corporation that provides a new model for business ... higher education assets and investment. U.S. Senator Cory ... CEO Joe Taylor, New Jersey Lieutenant Governor Kim ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... a man in critical condition was hospitalized due to septicemic ... in the bloodstream//. Another women from Bernalillo County died last ... the first to die. ,Bite from an infected ... and pets can transmit plague. ,C. Mack Sewell, ...
... has described the criticism of its alleged negligence of ... and principal of NBMCH, Dr J B Saha, said ... ,Yesterday around 200 HIV-positive persons under the banner of ... at NBMCH and alleged that the HIV patients were ...
... A Government official reports, ‘Indonesia hasn’t shared the genetic information ... of disease control and environment, Nyoman Kandun//, at the Indonesian ... considered and discussed by the Government before any public release ... has been used for research purpose. ,A chain ...
... (Indonesia), Mark Snelling, explains about relief operations in earthquake tore ... 5,700 were died and more than a thousand were injured ... even 24 hours here is an eternity – said latest ... collapsed and 200,000 lost their homes. ,The most ...
... researchers at the Oxford have found that high doses of ... doubles the risk of a heart attack if taken in ... Journal study also explains that there was no danger for ... the benefits for patients who depend on it to lead ...
... by killing thousands of rainbow trout.Due to an outbreak, fishes ... case of viral haemorrhagic septicaemia (VHS) attack on wild fish ... the river Ouse in Britain. ,Scottish island of ... industry officials says there is no harm to human beings. ...
Cached Medicine News:Health News:High Doses Of Common Pain killers Can Double The Chances Of Heart attack 2
... DPX Duo is a SmartBeam platform providing ... measurements of the two most clinical sites ... and at a low radiation dose., ... on Windows, optimizes productivity and ensures consistant ...
... the highly respected single-source CT solution, from ... plaque. With its proprietary STRATON X-ray tube, ... of 0.33s, virtually freezing the hearts motion. ... delivers unprecedented diagnostic detail with up to ...
... Blood Pressure Monitoring System (ABPM) allows health ... blood pressure throughout the day. ABPM therapy ... hypertension and the data generated can be ... compact monitor has sophisticated tracking capabilities to ...
... on Philips' iSyntax technology, which uniquely solves ... image data sets using standard desktop PCs, ... new infrastructure is required. iSite Enterprise delivers ... displayed view, making Philips' image delivery method, ...
Medicine Products: